Scholars Central

ArticlePublished Apr 2015

Superficial Basal Cell Carcinoma

Authors: Alex H Wong, Alexander KC Leung, Benjamin Barankin

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

A 62-year-old Caucasian woman presented with a slowly growing, asymptomatic, red plaque on her back that was first noted a year ago. Her family physician treated her with a topical antifungal and subsequently a topical steroid without success. Basal cell carcinoma (BCC) is generally defined as a locally invasive, slowly spreading tumor that rarely metastasizes, arising in the epidermis or hair follicles and in which, in particular, the peripheral cells usually simulate the basal cells of the epidermis. BCCs are a heterogeneous group of tumors that based on their clinical morphology can be classified most commonly into the following subtypes: nodular BCC, superficial BCC, sclerosing BCC, infiltrative BCC, micronodular BCC, and pigmented BCC. Superficial BCC is the second most common subtype, accounting for 9 to 17.5% of all cases. Unlike other BCC subtypes, it tends to have an earlier age of onset and a female predominance. It is the least aggressive subtype. Typically, the lesion presents as a solitary, well-defined, slowly growing, erythematous or pinkish, scaly patch or plaque that has a thin pearly border. The size varies from a few millimeters to several centimeters in diameter. The condition is usually asymptomatic. Occasionally, the lesion may be pigmented or ulcerated. Sites of predilection include the trunk, shoulders, and extremities. Diagnosis is often delayed as it is often mistaken for a dermatitis or tinea infection. For lesions occurring at a low-risk anatomic site (e.g., trunk and extremities) with distinct clinical borders and sizes less than 2 centimeters in diameter, treatment options include surgical excision, electrodessication with curettage, liquid nitrogen cryotherapy, topical immunotherapy (e.g. imiquimod), topical 5-fluorouracil, and photodynamic therapy. Patients should have regular follow-up at least yearly following diagnosis to monitor for local recurrence or the development of new BCCs or other skin cancers at other sites.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

Similar by topic

More from this journal

The newest in International Journal of Clinical & Medical Images.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalInternational Journal of Clinical & Medical Images
  • SubjectGeneral & Internal Medicine
  • BylineArticles whose byline prints “Alex H Wong”
  • BylineArticles whose byline prints “Alexander KC Leung”
  • BylineArticles whose byline prints “Benjamin Barankin”

For authors and organisers

Publish, present and keep up with your field

Find the right journal for your paper and submit your manuscript.

Photo: Pexels